|Research your Stock | Technical Calls | Live Market Action | Archives | Join Xchange|
Welcome to Market Insights.
In this edition, we have Firstcall India Equity recommending a pharma scrip, and CD Equisearch recommending a leader in the fitness industry. Furthermore, Nooresh Merani continues to share with us some more technical charts and his comments on them. Lastly, Way2wealth recommend Axis Bank, TVS Motors and PVR on technical grounds, while HDFC Sec recommend Vivimed Labs for 3-4 quarters.
If you like us. Please rate us on Facebook
|Vivimed Labs: Buy at CMP and add on declines|
|According to HDFC Sec, Vivimed Labs is a well-diversified company with a unique portfolio of products in Specialty Chemicals and Pharmaceuticals, with exports accounting for more than 50% of its revenues. Investors can buy the stock at CMP and average on dips in the band of Rs. 308-320 (~5.75x FY17E EPS) for sequential targets representing 7.5x FY17E EPS, ~8.75x FY17E EPS, and ~0.8x FY17E BV in 3-4 quarters.
|Weekly Equity Picks: Axis Bank, TVS Motors & PVR|
|According to Way2wealth, technical patterns in Axis Bank are suggesting that investors can buy the scrip at current level of 504.65 placing stop-loss at 483. Similarly in case of TVS Motors, the current price action along with placement of momentum indicator are suggesting that investors can buy this scrip above 249 placing stop-loss at 226. In case of PVR, traders are suggested to invest in this counter above 875 maintaining strict stop-loss at 830.
|CD Equisearch recommend a leader in fitness industry over a period of 9-12 months|
|According to CD Equiserach, this fitness company is ideally placed to gain from India’s economic growth, benefitting from favorable demographics, national presence in attractive locations, and rising prosperity. Hence, investors are recommended to buy the stock with a target price implying 14x FY 17e earnings (PEG ratio:1) over a period of 9-12 months.
|Buy this pharma scrip on expected strong sales-growth with high-margin products in rest of FY16|
|According to Firstcall India Equity, this pharma company expects strong sales growth with high-margin products, in the ensuing quarters of FY2016. At CMP of 2582.05, the stock P/E ratio is at 253.41xFY16E and 229.46xFY17E respectively. Investors are recommended to buy this scrip for mid-to long term investment.
|Featured Technical Call for today by Dharmesh Bhatt
CROMPTON GREAVES: 184-183 a crucial support where buying will be seen, keep stop loss of 180 to your buys
Upward side 190 and 193 crucial hurdles
|Ask an Expert - An answer to your question is just an e-mail away!|
|As the name suggests, this section enables you to ask our Experts your questions about finance and investing. We have Experts for every category, and you can choose which Expert you would like to direct your question to. Our Experts like Rakesh Rathod and Rakesh Sethi are prompt enough to answer all your queries, and have calmed concerns of several of our readers.
Do you have any such queries? Please feel free to post them on our Ask an Expert section and have your queries answered by our experts.
|Advertise with us | Write for us | Blog on Xchange | Archives | Feedback|